• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

西妥昔单抗治疗晚期结直肠癌患者的 PTEN 状态。

PTEN status in advanced colorectal cancer treated with cetuximab.

机构信息

Medical Oncology Unit, University Hospital, Parma 43100, Italy.

出版信息

Br J Cancer. 2010 Jan 5;102(1):162-4. doi: 10.1038/sj.bjc.6605471. Epub 2009 Dec 1.

DOI:10.1038/sj.bjc.6605471
PMID:19953097
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2813733/
Abstract

BACKGROUND

Loss of phosphatase and tensin homologue deleted in chromosome 10 (PTEN) function in advanced colorectal cancer (CRC) may represent one of the resistance mechanisms to cetuximab by interfering with the epidermal growth factor receptor signal transduction pathway.

METHODS

PTEN expression tested by indirect immunofluorescence was evaluated both on primary (n=43) and on metastatic (n=24) sites in CRC patients treated with cetuximab.

RESULTS

The loss of PTEN expression tested on metastatic sites was negatively associated with response (100% progressive disease (PD) in PTEN-negative cases vs 30% PD in PTEN-positive cases; P<0.05), PFS (0.8 vs 8.2 months; P<0.001) and OS (2.9 vs 14.2 months; P<0.001).

CONCLUSION

A potential role of PTEN in the anti-tumour activity of cetuximab could be hypothesised.

摘要

背景

在晚期结直肠癌（CRC）中，磷酸酶和张力蛋白同源物缺失于染色体 10（PTEN）功能的丧失可能代表了对西妥昔单抗产生耐药性的机制之一，通过干扰表皮生长因子受体信号转导通路。

方法

通过间接免疫荧光法检测 CRC 患者接受西妥昔单抗治疗时的原发（n=43）和转移（n=24）部位的 PTEN 表达。

结果

在转移部位检测到的 PTEN 表达缺失与反应（PTEN 阴性病例 100%进展性疾病（PD）与 PTEN 阳性病例 30% PD；P<0.05）、PFS（0.8 与 8.2 个月；P<0.001）和 OS（2.9 与 14.2 个月；P<0.001）呈负相关。

结论

可以假设 PTEN 在西妥昔单抗的抗肿瘤活性中发挥潜在作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/735e/2813733/d2caa0116431/6605471f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/735e/2813733/d2caa0116431/6605471f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/735e/2813733/d2caa0116431/6605471f1.jpg

相似文献

1
PTEN status in advanced colorectal cancer treated with cetuximab.西妥昔单抗治疗晚期结直肠癌患者的 PTEN 状态。
Br J Cancer. 2010 Jan 5;102(1):162-4. doi: 10.1038/sj.bjc.6605471. Epub 2009 Dec 1.
2
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.原发性肿瘤和转移灶中PTEN表达及KRAS突变对转移性结直肠癌患者从西妥昔单抗联合伊立替康治疗中获益的预测作用
J Clin Oncol. 2009 Jun 1;27(16):2622-9. doi: 10.1200/JCO.2008.20.2796. Epub 2009 Apr 27.
3
The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.表皮生长因子受体相关基因的状态可以预测西妥昔单抗联合化疗治疗化疗耐药转移性结直肠癌患者的预后和肿瘤反应。
J Surg Oncol. 2011 Nov 1;104(6):661-6. doi: 10.1002/jso.21993. Epub 2011 Jun 13.
4
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.在转移性结直肠癌中，PIK3CA突变并非对表皮生长因子受体抑制剂西妥昔单抗耐药的主要决定因素。
Clin Cancer Res. 2009 May 1;15(9):3184-8. doi: 10.1158/1078-0432.CCR-08-2961. Epub 2009 Apr 14.
5
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.西妥昔单抗联合卡培他滨和伊立替康对比西妥昔单抗联合卡培他滨和奥沙利铂作为转移性结直肠癌一线治疗：德国 AIO CRC 研究组的 AIO KRK-0104 随机试验。
J Clin Oncol. 2011 Mar 10;29(8):1050-8. doi: 10.1200/JCO.2010.31.1936. Epub 2011 Feb 7.
6
Cetuximab in previously treated colorectal cancer.西妥昔单抗用于先前接受过治疗的结直肠癌
Clin Colorectal Cancer. 2005 Apr;5 Suppl 1:S28-33. doi: 10.3816/ccc.2005.s.004.
7
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.西妥昔单抗联合伊立替康治疗难治性晚期结直肠癌患者的药物遗传学分析
J Clin Oncol. 2008 Mar 20;26(9):1427-34. doi: 10.1200/JCO.2007.12.4602.
8
Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.表皮生长因子受体（EGFR）和KRAS状态在接受抗EGFR单克隆抗体治疗的结直肠癌患者中的临床相关性
Cancer Treat Rev. 2009 May;35(3):262-71. doi: 10.1016/j.ctrv.2008.11.005. Epub 2008 Dec 30.
9
EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.表皮生长因子受体（EGFR）基因拷贝数可预测RAS野生型及RAS/ BRAF/PIK3CA野生型转移性结直肠癌患者对抗表皮生长因子受体治疗的反应。
Int J Cancer. 2017 Feb 15;140(4):922-929. doi: 10.1002/ijc.30507. Epub 2016 Nov 23.
10
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer.表皮生长因子受体相关突变状态与转移性结直肠癌三线西妥昔单抗-伊立替康的临床结果的相关性。
BMC Cancer. 2011 Mar 25;11:107. doi: 10.1186/1471-2407-11-107.

引用本文的文献

1
The role of negative hyperselection in metastatic colorectal cancer.阴性超选择在转移性结直肠癌中的作用。
J Gastrointest Oncol. 2024 Oct 31;15(5):2353-2357. doi: 10.21037/jgo-24-376. Epub 2024 Oct 16.
2
PTEN and P-4E-BP1 might be associated with postoperative recurrence of rectal cancer patients undergoing concurrent radiochemotherapy.PTEN 和 P-4E-BP1 可能与接受同期放化疗的直肠癌患者术后复发有关。
BMC Cancer. 2024 May 13;24(1):582. doi: 10.1186/s12885-024-12339-x.
3
SNHG4-mediated PTEN destabilization confers oxaliplatin resistance in colorectal cancer cells by inhibiting ferroptosis.

本文引用的文献

1
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.原发性肿瘤和转移灶中PTEN表达及KRAS突变对转移性结直肠癌患者从西妥昔单抗联合伊立替康治疗中获益的预测作用
J Clin Oncol. 2009 Jun 1;27(16):2622-9. doi: 10.1200/JCO.2008.20.2796. Epub 2009 Apr 27.
2
Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant.原发性结直肠癌及其相关转移部位中表皮生长因子受体（EGFR）和下游蛋白的不同程度失调可能具有临床相关性。
Br J Cancer. 2009 Apr 7;100(7):1087-94. doi: 10.1038/sj.bjc.6604848. Epub 2009 Mar 17.
3
SNHG4 通过稳定 PTEN 来抑制铁死亡从而赋予结直肠癌细胞奥沙利铂耐药性。
Apoptosis. 2024 Jun;29(5-6):835-848. doi: 10.1007/s10495-024-01948-3. Epub 2024 Apr 4.
4
Clinicopathological Significance of PTEN Expression and Its Prognostic Effect in Colorectal Adenocarcinoma Patients.PTEN表达在结直肠癌患者中的临床病理意义及其预后影响
Iran J Pathol. 2022 Spring;17(2):150-158. doi: 10.30699/IJP.2021.531779.2653. Epub 2022 Mar 8.
5
Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.转移性结直肠癌中抗 EGFR 治疗的耐药性：潜在机制与逆转策略。
J Exp Clin Cancer Res. 2021 Oct 18;40(1):328. doi: 10.1186/s13046-021-02130-2.
6
Evaluating the value of Amphiregulin, Phosphatase and Tensin Homologue (PTEN) and P21 Expression for Anti-EGFR Treatment in Metastatic Colorectal Carcinoma.评估 Amphiregulin、磷酸酶和张力蛋白同系物（PTEN）和 P21 表达在转移性结直肠癌抗 EGFR 治疗中的价值。
Asian Pac J Cancer Prev. 2021 Apr 1;22(4):1025-1034. doi: 10.31557/APJCP.2021.22.4.1025.
7
MicroRNA-Assisted Hormone Cell Signaling in Colorectal Cancer Resistance.微小 RNA 辅助激素细胞信号在结直肠癌耐药中的作用。
Cells. 2020 Dec 30;10(1):39. doi: 10.3390/cells10010039.
8
Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC.通过CD31评估的微血管密度可预测转移性结直肠癌患者接受贝伐单抗治疗后的临床获益：PassionATE研究结果，这是一项关于卡培他滨和伊立替康联合贝伐单抗，随后卡培他滨和奥沙利铂联合贝伐单抗或在转移性结直肠癌患者中采用相反顺序的转化性前瞻性II期研究。
Ther Adv Med Oncol. 2020 Aug 18;12:1758835920928635. doi: 10.1177/1758835920928635. eCollection 2020.
9
Molecular Pathogenesis and Classification of Colorectal Carcinoma.结直肠癌的分子发病机制与分类
Curr Colorectal Cancer Rep. 2020 Sep;16(5):97-106. doi: 10.1007/s11888-020-00458-z. Epub 2020 Aug 15.
10
Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC).结直肠癌（CRC）管理中实验室分子诊断进展的最新情况
Diagnostics (Basel). 2019 Dec 23;10(1):9. doi: 10.3390/diagnostics10010009.
EGFR antagonists in cancer treatment.
癌症治疗中的表皮生长因子受体拮抗剂
N Engl J Med. 2008 Mar 13;358(11):1160-74. doi: 10.1056/NEJMra0707704.
4
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.对107例前列腺癌进行的荧光原位杂交（FISH）分析表明，PTEN基因缺失与不良临床预后相关。
Br J Cancer. 2007 Sep 3;97(5):678-85. doi: 10.1038/sj.bjc.6603924. Epub 2007 Aug 14.
5
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.表皮生长因子受体（EGFR）基因拷贝数与结直肠癌抗EGFR治疗的临床反应：一项队列研究。
Lancet Oncol. 2005 May;6(5):279-86. doi: 10.1016/S1470-2045(05)70102-9.
6
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.西妥昔单抗在经免疫组织化学检测肿瘤不表达表皮生长因子受体的结直肠癌患者中显示出活性。
J Clin Oncol. 2005 Mar 20;23(9):1803-10. doi: 10.1200/JCO.2005.08.037. Epub 2005 Jan 27.
7
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.西妥昔单抗单药治疗及西妥昔单抗联合伊立替康治疗伊立替康难治性转移性结直肠癌。
N Engl J Med. 2004 Jul 22;351(4):337-45. doi: 10.1056/NEJMoa033025.
8
Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation.正在进行临床研究的表皮生长因子受体抑制剂的药代动力学和药效学特性。
Cancer Treat Rev. 2004 May;30(3):255-68. doi: 10.1016/j.ctrv.2003.10.003.
9
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.西妥昔单抗用于表达表皮生长因子受体的难治性结直肠癌患者的II期试验。
J Clin Oncol. 2004 Apr 1;22(7):1201-8. doi: 10.1200/JCO.2004.10.182. Epub 2004 Mar 1.
10
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.在表达表皮生长因子受体（EGF receptor）的肿瘤细胞中，第10号染色体缺失的磷酸酶及张力蛋白同源物（PTEN）/MMAC1/TEP的缺失会抵消表皮生长因子受体酪氨酸激酶抑制剂的抗肿瘤作用。
Oncogene. 2003 May 8;22(18):2812-22. doi: 10.1038/sj.onc.1206388.